193 related articles for article (PubMed ID: 19165424)
1. Role of intravitreal bevacizumab in the management of Eales' disease.
Chanana B; Azad RV; Patwardhan S
Int Ophthalmol; 2010 Feb; 30(1):57-61. PubMed ID: 19165424
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy.
Yang CS; Hung KC; Huang YM; Hsu WM
J Ocul Pharmacol Ther; 2013; 29(6):550-5. PubMed ID: 23495932
[TBL] [Abstract][Full Text] [Related]
3. Secondary rhegmatogenous retinal detachment following intravitreal bevacizumab in patients with vitreous hemorrhage or tractional retinal detachment secondary to Eales' disease.
Kumar A; Sehra SV; Thirumalesh MB; Gogia V
Graefes Arch Clin Exp Ophthalmol; 2012 May; 250(5):685-90. PubMed ID: 22169980
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal injection of bevacizumab in Eales disease.
Küçükerdönmez C; Akova YA; Yilmaz G
Ocul Immunol Inflamm; 2008; 16(1):63-5. PubMed ID: 18379947
[TBL] [Abstract][Full Text] [Related]
5. New classification system-based visual outcome in Eales' disease.
Saxena S; Kumar D
Indian J Ophthalmol; 2007; 55(4):267-9. PubMed ID: 17595474
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.
Spaide RF; Fisher YL
Retina; 2006 Mar; 26(3):275-8. PubMed ID: 16508426
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
[TBL] [Abstract][Full Text] [Related]
8. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma.
Batioğlu F; Astam N; Ozmert E
Int Ophthalmol; 2008 Feb; 28(1):59-61. PubMed ID: 17609852
[TBL] [Abstract][Full Text] [Related]
9. Role of intravitreal bevacizumab in Eales disease with dense vitreous hemorrhage: a prospective randomized control study.
Patwardhan SD; Azad R; Shah BM; Sharma Y
Retina; 2011 May; 31(5):866-70. PubMed ID: 21301382
[TBL] [Abstract][Full Text] [Related]
10. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab.
Saito Y; Higashide T; Takeda H; Murotani E; Ohkubo S; Sugiyama K
Am J Ophthalmol; 2010 Jun; 149(6):964-972.e1. PubMed ID: 20381786
[TBL] [Abstract][Full Text] [Related]
11. Combined diode laser cyclophotocoagulation and intravitreal bevacizumab (Avastin) in neovascular glaucoma.
Ghosh S; Singh D; Ruddle JB; Shiu M; Coote MA; Crowston JG
Clin Exp Ophthalmol; 2010 May; 38(4):353-7. PubMed ID: 20665941
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab (Avastin) as a treatment of the neovascular complications of laser-induced chorioretinal anastomosis for nonischaemic central retinal vein occlusion.
Fong KC; Barry C; McAllister IL
Clin Exp Ophthalmol; 2009 Jul; 37(5):485-9. PubMed ID: 19624345
[TBL] [Abstract][Full Text] [Related]
13. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations].
Małgorzata F
Klin Oczna; 2010; 112(7-9):213-6. PubMed ID: 21121123
[TBL] [Abstract][Full Text] [Related]
14. Rapid regression of extensive retinovitreal neovascularization secondary to branch retinal vein occlusion after a single intravitreal injection of bevacizumab.
Ahmadieh H; Moradian S; Malihi M
Int Ophthalmol; 2005; 26(4-5):191-3. PubMed ID: 17286185
[TBL] [Abstract][Full Text] [Related]
15. INTRAVITREAL BEVACIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Results From the Pan-American Collaborative Retina Study Group (PACORES) at 24 Months of Follow-up.
Arevalo JF; Lasave AF; Wu L; Maia M; Diaz-Llopis M; Alezzandrini AA; Brito M;
Retina; 2017 Feb; 37(2):334-343. PubMed ID: 27429384
[TBL] [Abstract][Full Text] [Related]
16. Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation.
Schmidinger G; Maar N; Bolz M; Scholda C; Schmidt-Erfurth U
Acta Ophthalmol; 2011 Feb; 89(1):76-81. PubMed ID: 21272288
[TBL] [Abstract][Full Text] [Related]
17. Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy.
Liu L; Wu WC; Yeung L; Wang NK; Kuo YH; Chao AN; Chen KJ; Chen TL; Lai CC; Hwang YS; Chen YP
Ophthalmic Surg Lasers Imaging; 2010; 41(1):72-7. PubMed ID: 20128573
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
[TBL] [Abstract][Full Text] [Related]
19. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects of laser photocoagulation and/or vitrectomy in Eales' disease.
Dehghan MH; Ahmadieh H; Soheilian M; Azarmina M; Mashayekhi A; Naghibozakerin J
Eur J Ophthalmol; 2005; 15(3):379-83. PubMed ID: 15945008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
